Corvus Pharmaceuticals, Inc. Common Stock CRVS
i
Market datapartial · fetched 2026-11-11T15:12:06.569Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:11:47.105728414Z
FundamentalsAlpha Vantage · unavailable
Corvus Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.06 | 99.3% | 13.3% | |||
| 25Δ | 10.30 | 100.0% | 11.8% | |||
| 30Δ | 10.55 | 100.6% | 10.4% | |||
| 35Δ | 10.80 | 101.3% | 9.0% | |||
| 40Δ | 11.02 | 100.5% | 7.7% | |||
| 45Δ | 11.13 | 93.0% | 6.9% | |||
| 50Δ | 11.43 | 126.4% | 8.6% | 11.24 | 85.6% | 6.0% |
| 55Δ | 11.22 | 141.5% | 8.4% | 11.35 | 78.1% | 5.2% |
| 60Δ | 11.00 | 156.1% | 8.2% | |||
| 65Δ | 10.75 | 143.6% | 6.7% | |||
| 70Δ | 10.50 | 131.0% | 5.2% | |||
| 75Δ | 10.25 | 118.5% | 3.6% | |||
| 80Δ | 10.01 | 106.0% | 2.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.06
- IV
- 99.3%
- B/E move
- 13.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.30
- IV
- 100.0%
- B/E move
- 11.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.55
- IV
- 100.6%
- B/E move
- 10.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.80
- IV
- 101.3%
- B/E move
- 9.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.02
- IV
- 100.5%
- B/E move
- 7.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.13
- IV
- 93.0%
- B/E move
- 6.9%
50Δ
- Pseudo strike
- 11.43
- IV
- 126.4%
- B/E move
- 8.6%
- Pseudo strike
- 11.24
- IV
- 85.6%
- B/E move
- 6.0%
55Δ
- Pseudo strike
- 11.22
- IV
- 141.5%
- B/E move
- 8.4%
- Pseudo strike
- 11.35
- IV
- 78.1%
- B/E move
- 5.2%
60Δ
- Pseudo strike
- 11.00
- IV
- 156.1%
- B/E move
- 8.2%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 10.75
- IV
- 143.6%
- B/E move
- 6.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 10.50
- IV
- 131.0%
- B/E move
- 5.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 10.25
- IV
- 118.5%
- B/E move
- 3.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 10.01
- IV
- 106.0%
- B/E move
- 2.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 104.70% | |
| 151.46% | |
| 117.58% | |
| 140.00% | |
| 115.00% | |
| 113.25% | |
| 85.09% | |
| 99.38% | |
| 114.51% | |
| 154.87% |
Biotechnology
CTMX
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
More →CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →DFTX
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New…
More →DMAC
Description unavailable
More →